PSMB9 and nasopharyngeal carcinoma: A phase I clinical trial of MVA-EL showed that among 18 NPC patients receiving intradermal immunization, 15 patients exhibited a twofold increase in T-cell responses to EBNA1 and LMP2 antigens [169] (Table 2).